Boobalan Pachaiyappan
Stock Analyst at Roth Capital
(4.61)
# 175
Out of 5,106 analysts
24
Total ratings
58.33%
Success rate
45.58%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OVID Ovid Therapeutics | Initiates: Buy | $3 | $1.81 | +65.75% | 1 | Dec 11, 2025 | |
| CING Cingulate | Maintains: Buy | $17 → $16 | $4.06 | +294.09% | 4 | Nov 19, 2025 | |
| PYPD PolyPid | Maintains: Buy | $10 → $9 | $3.90 | +130.77% | 3 | Nov 13, 2025 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $12 → $13 | $28.90 | -55.02% | 3 | Nov 12, 2025 | |
| RNA Avidity Biosciences | Initiates: Buy | $62 | $72.14 | -14.06% | 1 | Sep 17, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Reiterates: Buy | $7 → $3 | $0.32 | +833.71% | 2 | Aug 18, 2025 | |
| LGVN Longeveron | Maintains: Buy | $10 → $3 | $0.54 | +454.53% | 2 | Aug 15, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 → $6 | $3.08 | +94.81% | 3 | Aug 13, 2025 | |
| CRVO CervoMed | Reiterates: Buy | $20 → $16 | $8.42 | +90.02% | 4 | Aug 12, 2025 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $10.63 | +172.81% | 1 | Dec 5, 2024 |
Ovid Therapeutics
Dec 11, 2025
Initiates: Buy
Price Target: $3
Current: $1.81
Upside: +65.75%
Cingulate
Nov 19, 2025
Maintains: Buy
Price Target: $17 → $16
Current: $4.06
Upside: +294.09%
PolyPid
Nov 13, 2025
Maintains: Buy
Price Target: $10 → $9
Current: $3.90
Upside: +130.77%
Capricor Therapeutics
Nov 12, 2025
Maintains: Buy
Price Target: $12 → $13
Current: $28.90
Upside: -55.02%
Avidity Biosciences
Sep 17, 2025
Initiates: Buy
Price Target: $62
Current: $72.14
Upside: -14.06%
Reviva Pharmaceuticals Holdings
Aug 18, 2025
Reiterates: Buy
Price Target: $7 → $3
Current: $0.32
Upside: +833.71%
Longeveron
Aug 15, 2025
Maintains: Buy
Price Target: $10 → $3
Current: $0.54
Upside: +454.53%
Gain Therapeutics
Aug 13, 2025
Maintains: Buy
Price Target: $7 → $6
Current: $3.08
Upside: +94.81%
CervoMed
Aug 12, 2025
Reiterates: Buy
Price Target: $20 → $16
Current: $8.42
Upside: +90.02%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $10.63
Upside: +172.81%